MCL1 and leukemia: Looking forward, it is thus critical to determine, especially in the setting of T-ALL, the molecular mechanisms by which the PTEN/PI3K/Akt/GSK3 axis participates in Fbw7-mediated destruction of Mcl-1, and to evaluate whether Akt or mTOR inhibitors could be a novel anti-leukemia therapeutic option to trigger apoptosis by decreasing Mcl-1 protein abundance, especially for those who are PTEN-deficient.